Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Lanreotide treatment for patients with later-stage autosomal dominant polycystic kidney disease ...
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia Randomized, single-blinded study. Patients with NETs received ...
The somatostatin analogue lanreotide (Somatuline, Ipsen) is significantly better than placebo for controlling progression of many types of metastatic neuroendocrine tumors (NETs), according to the ...
The US Food and Drug Administration (FDA) has approved lanreotide (Somatuline, Ipsen Pharma) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or ...
Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for ...
Insulin-like growth factor I and growth hormone levels were adequately controlled on 4-weekly injections in nine patients. In these patients the effect of increasing the time interval between ...
The Food and Drug Administration has approved Somatuline Depot (lanreotide) for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results